Enzyme replacement therapy (ERT) is a medical treatment which replaces an enzyme that is deficient or absent in the body. Usually, this is done by giving the patient an intravenous (IV) infusion of a solution containing the enzyme.
Scope of the Report:The classification of enzyme replacement therapy includes injectable agents and oral agents, and the revenue proportion of injectable agents in 2017 is about 62.38%, and the proportion is in increasing trend from 2013 to 2017.
North America is the largest consumption place, with a consumption market share nearly 70.77% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 21.25%.
Market competition is intense. Sanofi, Shire, BioMarin, AbbVie , etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
The global Enzyme Replacement Therapy market is valued at 7400 million USD in 2018 and is expected to reach 15800 million USD by the end of 2026, growing at a CAGR of 13.4% between 2020 and 2026.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Enzyme Replacement Therapy.
Europe also play important roles in global market, with market size of xx million USD in 2020 and will be xx million USD in 2026, with a CAGR of xx%.
This report studies the Enzyme Replacement Therapy market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Enzyme Replacement Therapy market by product type and applications/end industries.
Market Segment by Companies, this report covers Sanofi
Shire
BioMarin
AbbVieÊ
Alexion
Allergan
Horizon Pharma
Johnson & Johnson
Actelion
Recordati Rare Diseases
Pfizer
Digestive Care
Leadiant Biosciences
Market Segment by Regions, regional analysis covers North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers Injectable Agents
Oral Agents
Market Segment by Applications, can be divided into Gaucher Disease
Fabry Disease
MPS Disease
Gastrointestinal Disease
Others
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.